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Transcriptional Enhancer Factor Domain 
Family member 4 Exerts an Oncogenic 
Role in Hepatocellular Carcinoma by 
Hippo-Independent Regulation of Heat 
Shock Protein 70 Family Members
Mairene Coto-Llerena ,1,2* Nadia Tosti,1* Stephanie Taha-Mehlitz,2,3 Venkatesh Kancherla,1 Viola Paradiso,1 John Gallon ,2 
Gaia Bianco,2 Andrea Garofoli,1 Souvik Ghosh ,4 Fengyuan Tang,5 Caner Ercan,1 Gerhard M. Christofori,5 Matthias S. Matter,1 
Raoul A. Droeser,3 Mihaela Zavolan,4 Savas D. Soysal,3 Markus von Flüe,3 Otto Kollmar,3 Luigi M. Terracciano,1   
Charlotte K. Y. Ng ,6 and Salvatore Piscuoglio 1,2
Transcriptional enhancer factor domain family member 4 (TEAD4) is a downstream effector of the conserved Hippo 
signaling pathway, regulating the expression of genes involved in cell proliferation and differentiation. It is up-regu-
lated in several cancer types and is associated with metastasis and poor prognosis. However, its role in hepatocellular 
carcinoma (HCC) remains largely unexplored. Using data from The Cancer Genome Atlas, we found that TEAD4 
was overexpressed in HCC and was associated with aggressive HCC features and worse outcome. Overexpression of 
TEAD4 significantly increased proliferation and migration rates in HCC cells in vitro as well as tumor growth in 
vivo. Additionally, RNA sequencing analysis of TEAD4-overexpressing HCC cells demonstrated that TEAD4 over-
expression was associated with the up-regulation of genes involved in epithelial-to-mesenchymal transition, prolif-
eration, and protein-folding pathways. Among the most up-regulated genes following TEAD4 overexpression were 
the 70-kDa heat shock protein (HSP70) family members HSPA6 and HSPA1A. Chromatin immunoprecipitation– 
quantitative real-time polymerase chain reaction experiments demonstrated that TEAD4 regulates HSPA6 and HSPA1A 
expression by directly binding to their promoter and enhancer regions. The pharmacologic inhibition of HSP70 ex-
pression in TEAD4-overexpressing cells reduced the effect of TEAD4 on cell proliferation. Finally, by overexpressing 
TEAD4 in yes-associated protein (YAP)/transcriptional coactivator with PDZ binding motif (TAZ)-knockdown HCC 
cells, we showed that the effect of TEAD4 on cell proliferation and its regulation of HSP70 expression does not 
require YAP and TAZ, the main effectors of the Hippo signaling pathway. Conclusion: A novel Hippo-independent 
mechanism for TEAD4 promotes cell proliferation and tumor growth in HCC by directly regulating HSP70 family 
members. (Hepatology Communications 2021;5:661-674).
Transcriptional enhancer factor domain (TEAD) proteins are a family of transcription factors that bind the consensus 5′-CATTCCA/T-3′ 
sequence through their shared TEA DNA binding 
domain.(1) TEAD-regulated transcription strictly 
depends on the binding of TEAD transcription fac-
tors with various coactivators,(2,3) among which are 
the yes-associated protein (YAP) and transcriptional 
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Gene Ontology; GSEA, gene set enrichment analysis; HCC, hepatocellular carcinoma; IgG, immunoglobulin; IHC, immunochemistry; kb, kilobase; 
KNK437, heat shock protein family A inhibitor 1; qPCR, quantitative real-time polymerase chain reaction; qRT-PCR, quantitative reverse-
transcription polymerase chain reaction; seq, sequencing; TAZ, transcriptional coactivator with PDZ binding motif; TCGA, The Cancer Genome 
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coactivator with PDZ binding motif (TAZ), two major 
effectors of the Hippo signaling pathway,(4,5) and the 
vestigial-like protein 1 (VGLL1).(6) In mammals, 
TEADs are highly conserved and widely expressed(7,8) 
and play a pivotal role in development by mediating 
cell proliferation and organ size control through the 
Hippo signaling pathway.(9) In cancer cells, TEADs 
regulate proliferation, migration, differentiation, 
epithelial-to-mesenchymal transition (EMT), apop-
tosis, and invasion.(10) In particular, TEAD factors 
regulate the expression of progrowth factors, such 
as connective tissue growth factor (CTGF),(10,11)   
cysteine-rich angiogenic inducer 61 (Cyr61),(11) AXL 
receptor tyrosine kinase (AXL),(12) MYC proto- 
oncogene bHLH transcription factor (Myc),(13) bac-
uloviral inhibitor of apoptosis repeat-containing 5 
(survivin),(13) and insulin-like growth factor binding 
protein 5 (IGFBP5).(6) Furthermore, overexpression 
of TEADs and their association with a poor clinical 
outcome have been reported in many cancer types, 
including breast, lung, prostate, colon, and gastric can-
cers as well as melanoma and glioblastoma.(14-16)
TEAD family member 4 (TEAD4), the gene 
encoding for the transcriptional enhancer factor 
(TEF)-3, is overexpressed in several tumor types, 
such as breast and gastric cancers,(16) as well as 
hepatoblastoma, the most common type of pedi-
atric liver cancer.(17) Notably, TEAD4 acts as an 
oncogene through Hippo signaling-dependent(18) 
and signaling-independent mechanisms.(6,15) In 
hepatocellular carcinoma (HCC), it is known that 
TEAD4 acts through the Hippo signaling path-
way, wherein the TEAD4/YAP complex cooper-
ates with forkhead box M1 (FOXM1) in inducing 
chromosome instability.(19) It has also been shown 
that up-regulation of the YAP2/TEAD4 axis by 
sirtuin 1 (SIRT1) deacetylation of YAP2 promotes 
HCC cell proliferation.(20) Furthermore, TEAD4/
YAP and hepatocyte nuclear factor 4α (HNF4α) 
regulate hepatocarcinogenesis by reciprocal repres-
sion in mice and rats.(21) Thus, until now, TEAD4 
was thought to play a YAP-dependent role in HCC 
oncogenesis.
In this study, we show that TEAD4 is overex-
pressed in a subset of HCC and that it promotes 
cell proliferation in HCC cells both in vitro and 
in vivo. We further show that TEAD4 directly regu-
lates HSP70 in a Hippo-independent mechanism.
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HCC-derived cell lines (HepG2, SNU449, HLE, 
and Huh7) were maintained in a 5% CO2-humidified 
atmosphere at 37°C and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum, 1% penicillin/streptomycin (Bio-Concept, 
Allschwil, Switzerland), and 1% minimal essential 
medium–nonessential amino acids (ThermoFisher 
Scientific, Basel, Switzerland). Stable YAP- and TAZ-
knockdown Huh7 and SNU449 cell lines (described in 
Tang et al.(22)) and their respective controls were main-
tained in complete medium supplemented with puro-
mycin (1 μg/mL). All cell lines were confirmed negative 
for mycoplasma infection using the polymerase chain 
reaction (PCR)-based Universal Mycoplasma Detection 
kit (American Type Culture Collection, Manassas, VA). 
For HSP70 inhibitor 1 (KNK437; CAS 218924-25-5; 
Calbiochem, Sigma-Aldrich, St. Louis, MO), cells were 
incubated with 100 μM of the inhibitor and the corre-
sponding dimethyl sulfoxide (DMSO) control.
Human samples
Ten human, unselected, nonconsecutive HCCs 
retrieved from the archives of the Institute of Medical 
Genetics and Pathology at the University Hospital 
Basel (Basel, Switzerland) were included in this study. 
These 10 samples had already been prescreened for 
HSP70 protein expression. The study was performed 
in accordance with the Helsinki Declaration and 
approved by the Ethics Committee of Basel. Data 
were collected retrospectively in a nonstratified and 
nonmatched manner, including patient age, tumor 
diameter, location, prognostic tumor/prognostic node 
stage, grade, histologic subtype, and vascular invasion.
immunoHistoCHemistRy
Immunohistochemistry (IHC) was performed as 
described.(23) Details are presented in the Supporting 
Information.
plasmiDs anD tRansFeCtion
For TEAD4 overexpression, pLV[Exp]-enhanced 
green fluorescent protein (EGFP)/Neo-EF1A> 
hTEAD4 was designed and ordered on the vector 
builder website (https://en.vecto rbuil der.com/), and 
the empty control vector was plasmid cytomegalovi-
rus (pCMV)-mir EGFP. For TEAD4 silencing, pSu-
per-retro-puro empty vector and pSuper-retro-puro 
shTEAD1/3/4 were adapted from Zhao et al.(11) The 
expression vectors were transiently transfected using 
the jetPRIME transfection reagent (Polyplus, Illkirch, 
France) following the manufacturer’s instructions. The 
expression of the plasmids was evaluated by western 
blot and quantitative reverse-transcription (qRT)-
PCR analysis. Cells were harvested 48  hours after 
transfection for further experiments.
pRotein eXtRaCtion 
anD WesteRn Blot Rna 
eXtRaCtion anD qRt-pCR anD 
Rna seQuenCing
Protein extraction and western blot RNA 
extraction along with qRT-PCR and RNA sequenc-




Proliferation and cell migration assays were per-
formed using the xCELLigence Real-Time Cell 
Analysis-dual purpose (ACEA Biosciences, San 
Diego, CA) system. All experiments were per-
formed in triplicate. Results are shown as mean ± SD. 
Statistical significance was assessed by the t test.
WounD-Healing assay
Twenty-four hours after transfection, a 100-μL 
micropipette tip was used to create a scratch in the 
cell monolayer in each well of the six-well plate. To 
monitor the wound closure, representative phase- 
contrast images of each well were taken at 0, 8, 12, 
and 24 hours after the scratch was made. Each experi-
mental condition was evaluated in triplicate. Statistical 
significance was assessed by the t test.
CHoRioallantoiC memBRane 
assay
Fertilized chicken eggs were obtained from a 
local hatchery (Gepro Geflügelzucht AG, Flawil, 
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Switzerland) at day 1 of gestation and were incubated 
at 37°C with 60% humidity for 10  days. The cells 
were harvested 24 hours after transfection, suspended 
(2  ×  106 cells per chorioallantoic membrane [CAM] 
assay) in 10 μL of medium (DMEM), mixed 1:1 with 
matrigel (Matrigel Matrix; Ref. 354234; Corning, 
Tewksbury, MA), and grafted onto the CAM of 
9-day-old chicken embryos. The chicken embryos 
were maintained in ovo at 37°C for another 4  days, 
followed by removal of the tumors. Pictures of each 
tumor were taken with a Canon EOS 1100D digi-
tal camera. Tumor size measurements were performed 
by averaging the volume (height × width × width) of 
each tumor, using ImageJ as described.(24)
CelltiteR-glo Cell ViaBility 
assay
CellTiter-Glo (G7573; Promega, Dübendorf, 
Switzerland) was used to determine the number of 
viable cells based on adenosine triphosphate content. 
Twenty-four hours after transfection, cells were seeded 
in a 96-well plate. After 8 hours, drug treatment was 
added to the cells and cell viability was measured by 
adding 100  μL of CellTiter-Glo/well at 24, 48, and 
72  hours posttreatment. Statistical significance was 
assessed by multiple t test. In sorafenib experiments, 
results were normalized to DMSO. Curve fitting was 
performed using Prism software (GraphPad Software, 
San Diego, CA) and the nonlinear regression equation.
analysis oF CHRomatin 
immunopReCipitation 
seQuenCing Data
Chromatin immunoprecipitation (ChIP)-seq data 
for TEAD4 in the HepG2 human liver cell line were 
produced using mouse monoclonal immunoglobulin 
G (IgG) raised against recombinant protein TEAD4 
and were obtained from the Gene Expression 
Omnibus (accession number GSM1010875).(25) 
Processed data as an hg19 bigWig file were loaded 
into Integrative Genomics Viewer,(26) and the “Find 
Motif ” tool was used to search for the most con-
served bases of TEAD4 binding motif within regions 
of TEAD4 ChIP-seq peaks. TEAD4 binding motif 
was obtained from the JASPAR 2018 database.(27) 
TEAD4 enhancers were called from the TEAD4 
broadPeak BED file using the Cognitive Reliability 
and Error Analysis Method (CREAM),(28) with 
the options WScutoff = 1.5, Minlength = 1000, and 
peakNumMin  =  2. CREAM calls enhancers based 
on clusters of peaks, taking into account the distri-
bution of distances between peaks in ChIP-seq data 
from a given sample.
Chip
Cells from four 10-cm Petri dishes at 70%-80% 
confluence were crosslinked in 1% formaldehyde for 
10  minutes with continuous shaking. The crosslink-
ing was stopped by adding 0.15  M glycine while 
continuing shaking. After collecting the cells by 
scraping, the pellet was washed 3 times with cold 
phosphate-buffered saline. The nuclei of the cells 
were isolated and lysed. Chromatin shearing was 
performed using Bioruptor Pico (Diagenode, Liège, 
Belgium). The number of cycles and the settings were 
as described.(29) At the same time, the antibody was 
coupled with magnetic protein G beads (100-03D; 
Invitrogen, Carlsbad, CA) by incubating 75  μL of 
protein G beads with 10  μg of TEAD4 antibody 
(TEF-3, sc-101184; Santa Cruz Biotechnology, 
Dallas, TX) or 10 μg of mouse IgG (sc-2025; Santa 
Cruz Biotechnology) as a negative control for 1 hour 
with constant rotation. At the end of the sonication 
process, an aliquot of the chromatin was kept as input 
control for every sample and an equal amount of son-
icated chromatin was incubated with the previously 
produced antibody-coupled magnetic beads at 4°C 
overnight while rotating. The samples were washed 
and then eluted (all buffers are as described in the 
original protocol from Blecher-Gonen et al.(30)). 
Ribonuclease treatment and then proteinase K treat-
ment were performed on all samples, followed by 
overnight reverse crosslinking at 65°C with continu-
ous shaking. DNA purification was performed using 
Agencourt AMPure XP (A63880; Beckman Coulter, 
Brea, CA). TEAD4 abundance on specific target gene 
promoters was quantified by qRT-PCR compared to 
IgG negative control. Primer sequences are listed in 
Supporting Table S1.
statistiCal analysis
Statistical analyses were performed using GraphPad 
Prism version 6.0 and R. For in vitro and in vivo 
studies, statistical significance was determined by the 
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two-tailed unpaired Student t test. Differences were 
considered statistically significant at P  <  0.05. All 
experiments were performed at least twice. The sta-
tistical parameters (i.e., the exact value of n, P values) 
are noted in the figures and figure legends. Results are 
shown as mean ± SD.
analysis of the Cancer genome atlas 
liver Data set
Analysis of The Cancer Genome Atlas (TCGA) liver 
data set is described in the Supporting Information.
Results
teaD4 oVeReXpRession 
pRomotes HCC tumoR 
gRoWtH IN VITRO anD IN VIVO
As TEAD4 overexpression has been associated with 
poor clinical outcome in a number of cancer entities, 
we asked whether TEAD4 overexpression plays a 
similar role in HCC. We first confirmed that TEAD4 
was overexpressed in HCC using the TCGA data set. 
Compared to the nontumoral livers, HCCs showed 
TEAD4 overexpression (P  <  0.001, Mann-Whitney 
U test) in 21% (n  =  73/371) of cases (Supporting 
Fig.  S1A,B). Additionally, we observed that TEAD4 
expression was associated with aggressive HCC fea-
tures, such as high Edmondson grade, high stage, and 
histologic changes, more frequently observed in severe 
diseases, such as the presence of necrosis, pleomor-
phic, and multinucleated cells (P  <  0.05; Supporting 
Fig.  S1C). Additionally, TEAD4-overexpressing 
tumors were more enriched in Hoshida molecular 
subtype S1, which is associated with higher prolif-
eration and worse outcome (Supporting Fig.  S1C). 
Furthermore, we observed that TEAD4 overexpres-
sion was associated with worse overall survival and 
was independently prognostic in patients with HCC 
in univariate and multivariate models (hazard ratio, 
1.52; 95% confidence interval, 1.00-2.29) (Supporting 
Fig. S1D; Supporting Table S2).
Having determined that TEAD4 is indeed over-
expressed in HCC, we modulated the expression of 
TEAD4 in HCC cell lines, examined its effect on cell 
growth, and further exploited these models to dis-
sect the possible oncogenic role of TEAD4. Using a 
complementary DNA construct, we overexpressed 
TEAD4 in two HCC cell lines with low endogenous 
levels of TEAD4 expression (Huh7 and SNU449; 
Supporting Fig.  S2A,B). We further used short- 
hairpin RNAs to silence TEAD4 in two HCC cell 
lines with high endogenous levels of TEAD4 expres-
sion (HLE and HepG2; Supporting Fig. S2A,B). We 
observed that TEAD4 overexpression significantly 
increased proliferation as well as cell migration in 
both Huh7 and SNU449 cells (Fig. 1A,B; Supporting 
Fig.  S2C,D). On the contrary, TEAD4-silenced 
HLE and HepG2 cells significantly proliferated and 
migrated less compared to control cells (Fig.  1A,B; 
Supporting Fig.  S2C,D). The wound-healing assay 
further confirmed the role of TEAD4 in regulating 
the migration potential of HCC cells. Indeed, forced 
expression of TEAD4 in Huh7 led to an increase in 
the gap closure rate, while TEAD4 silencing slowed 
the speed of gap closure in HLE cells (P  <  0.01, 
Mann-Whitney U test) (Fig.  1C). Finally, because 
sorafenib is still the primary choice for first-line treat-
ment of patients with HCC, we tested if the modula-
tion of TEAD4 expression might affect the response 
to sorafenib. Our results showed that overexpression 
or silencing of TEAD4 did not alter the sensitivity of 
the cells to sorafenib (Supporting Fig. S2E).
To further demonstrate the oncogenic role of 
TEAD4 in HCC, we xenotransplanted TEAD4-
overexpressing and control Huh7 cells into the 
chicken CAM and assessed tumor growth in vivo 
(Fig.  2A). Engraftment of tumor cells in the CAM 
has been successfully used as a model of tumorigen-
esis.(31) Indeed, it has been shown that this densely 
vascularized extraembryonic tissue enables a fast, 
reproducible, and precise analysis of the principal 
steps of tumor progression and is a powerful tool for 
preclinical in vivo studies.(32) Briefly, 24  hours post-
transfection, cells were harvested and resuspended in 
matrigel before being seeded into the CAMs. After 
4 days, eggs were screened for tumor formation and 
tumors were harvested for quantification and fur-
ther analysis. In accordance with the results obtained 
in vitro, TEAD4-overexpressing engrafted cells 
formed significantly larger tumors compared to con-
trol cells (Fig.  2B,C; P  <  0.05, Mann-Whitney U 
test). IHC and western blot analysis confirmed that 
the resected tumors were indeed of human origin and 
that TEAD4 overexpression could still be detected 5 
days posttransfection (Fig. 2D).
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Taken together, our in vitro and in vivo data pro-
vide compelling evidence of the oncogenic role of 
TEAD4 in HCC. In particular, we demonstrate the 
role of TEAD4 in promoting proliferation and migra-
tion of liver cancer cells.
teaD4 Regulates Cell 
DiFFeRentiation anD 
pRoliFeRation anD tHe 
eXpRession oF Hsp70 Family 
genes
To define the transcriptional changes induced by 
TEAD4 overexpression, we performed RNA-seq on 
Huh7 cells overexpressing TEAD4 (n  =  4) or control 
vector (n  =  4; Fig.  3A). Differential expression analy-
sis identified 569 up-regulated and 316 down-regulated 
genes following TEAD4 overexpression (quasi-likelihood 
F test, adjusted P < 0.05) (Fig. 3B; Supporting Table S3). 
Gene set enrichment analysis (GSEA)(33) revealed the 
up-regulated genes were involved in pathways, such as 
myogenesis, EMT, and the P53 pathway, all associated 
with cell differentiation and proliferation (Fig.  3C). 
Conversely, we observed a down-regulation of gene sets 
involved in metabolism, such as protein secretion and 
bile acid metabolism (Fig. 3C). These results are consis-
tent with the aggressive phenotype we observed in our 
in vitro and in vivo models following TEAD4 overex-
pression as well as with the well-known role of TEAD 
proteins in regulating EMT and proliferation.(10)
In-depth analysis of the RNA-seq data revealed 
altered expression of the HSP family members, 
including some small HSPs (HSPB9 and HSPB1), 
HSP40 (DNAJA4), and HSP70 (HSPA1A, HSPA1B, 
and HSPA6). Furthermore, the set of HSP70 genes 
defined by Klimczak et al.(34) was found to be sig-
nificantly enriched in the TEAD4-overexpressing 
Huh7 cells (P  <  0.05, GSEA; Fig.  3D), while other 
HSP gene sets (HSP40 and HSP90) were not signifi-
cantly altered. In line with this, GSEA using Gene 
Ontology (GO) pathways showed enrichment of gene 
sets downstream of the HSP genes, such as those 
involved in HSP-binding protein-folding chaperones 
and unfolded protein binding (Fig. 3E). Surprisingly, 
the canonical Hippo targets seem not to be up- 
regulated in TEAD4-overexpressing cells, suggesting a 
potential Hippo-independent role of TEAD4 in regu-
lating HSP70 family members.
Fig. 1. Modulation of TEAD4 expression level impacts cell proliferation and migration. (A) Proliferation and (B) migration kinetics 
of TEAD4-overexpressing (TEAD4ox) Huh7 and TEAD4-silenced (shTEAD4) HLE cells compared to their respective controls. (C) 
Wound-healing assay in TEAD4-overexpressing Huh7 and TEAD4-silenced HLE cells compared to their respective controls at specific 
time points. Representative pictures at time points 0 and 24 hours after scratch are shown for each condition. Scale bar in (C), 1 cm. 
Statistical significance was determined by the t test; *P < 0.05,**P < 0.01. Data are mean ± SD. Abbreviations: h, hours; sh, short hairpin.
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Among the HSP70 genes, HSPA1A and HSPA6 
were the most significantly up-regulated genes follow-
ing TEAD4 overexpression (Fig.  3B). Using qPCR, 
we confirmed that overexpression of TEAD4 led to a 
significant increase in HSPA6 and HSPA1A expression 
in our in vitro models (Huh7 and SNU449; Fig. 3F). 
Our results suggested that HSP70 is a novel family of 
TEAD4 target genes in HCC.
teaD4 DiReCtly Regulates 
tHe tRansCRiption oF Hsp70 
Family genes
The HSP70 family comprises 13 gene products that 
differ from each other by expression level, subcellular 
location, and amino acid composition. Following expo-
sure to different stressors, HSP70s bind to misfolded 
proteins and prevent their aggregation. As HSP70 fam-
ily members and their overexpression have been shown 
to play an oncogenic role in different cancer types,(35,36) 
including HCC,(37,38) we asked if HSP70 family genes 
were direct transcriptional targets of TEAD4. Because 
HSPA6 and HSPA1A were the most up-regulated genes 
following TEAD4 overexpression (Fig. 3B), we focused 
on these two members of the family. We analyzed a 
set of peak calls from TEAD4 ChIP-seq performed 
on the HepG2 cell line.(25) Interestingly, we observed 
a TEAD4 peak within the HSPA6 promoter region, 
~100 base pairs (bp) upstream of the transcription 
starting site (TSS), that contained two regions with the 
TEAD4 binding motif (chr1:161493541-161493545 
and chr1:161493648-161493652; Fig.  4A). Additional 
analysis of the peak calls using CREAM(28) identified 
a cluster of TEAD4 peaks ~50 kilobases (kb) upstream 
of the HSPA6 promoter (i.e., a TEAD4 enhancer, 
chr1:31,776,368-31,832,367; Fig.  4A) and another 
enhancer ~47 kb downstream of the HSPA1A promoter 
(chr6:31,830,291-38,133,978; Fig.  4A), both well 
Fig. 2. TEAD4 overexpression increases tumor growth in vivo. (A) Schematic representation of the CAM assay. (B) Photographs of 
TEAD4-overexpressing or control Huh7 cells implanted in CAMs and grown for 4 days postimplantation. (C) Volume of tumors derived 
from the CAM experiment (n ≥ 7 tumors over two independent experiments). Values are normalized to the mean volume of control. 
(D) TEAD4 expression in Huh7 tumors extracted 4 days postimplantation analyzed by western blot (left) and IHC (right). Tumoral cells 
were immunostained with the TEAD4 antibody. Scale bars, (B) 1 cm and (D) 50 μm and 20 μm. Statistical significance was determined 
by the Mann-Whitney U test; *P < 0.05. Data are mean ± SD. Abbreviations: H&E, hematoxylin and eosin; ox, overexpression.
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within the 100-kb range of most promoter-enhancer 
interactions.(39) Peaks in both enhancers and at the gene 
promoters were also confirmed to contain the TEAD4 
binding motif (Fig. 4A).
To confirm that TEAD4 directly binds to the pro-
moter region of the HSPA6 gene and the enhancer 
region of HSPA1A, we performed ChIP in TEAD4-
overexpressing Huh7 cells, using anti-TEAD4 
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antibody or IgG followed by qPCR. Using primers 
spanning the predicted TEAD4 binding region on 
the HSPA6 promoter, the HSPA1A enhancer region, 
and the known TEAD4 target CTGF promoter,(7) we 
confirmed that TEAD4 indeed binds to the HSPA6 
promoter and HSPA1A enhancer region (Fig. 4B).
To corroborate the results obtained in vitro we 
performed IHC staining on 10 HCC samples using 
TEAD4 and HSP70 antibodies. Analysis of this 
cohort revealed that samples positive for TEAD4 
expression were also positive for HSP70 and vice 
versa (P  =  0.06, Spearman correlation test; Fig.  4C). 
Of these 10 samples, eight were positive for HSP70 
and two were negative. Six out of eight HCCs positive 
for HSP70 were also positive for TEAD4 (Fig. 4C), 
while the two HCCs negative for HSP70 were also 
negative for TEAD4.
Taken together, our results demonstrate that HSPA6 
and HSPA1A are transcriptional targets of TEAD4 in 
HCC through both TEAD4-promoter and TEAD4-
enhancer interactions.
onCogeniC eFFeCts oF teaD4 
aRe meDiateD tHRougH its 
up-Regulation oF Hsp70
Given that the HSP70 family genes are direct 
transcriptional targets of TEAD4 and that HSP70s 
are known to play an oncogenic role in various can-
cer types, including HCC,(37) we hypothesized that 
the oncogenic effects of TEAD4 may be at least 
partially mediated by its up-regulation of HSP70. 
We therefore inhibited HSP70 pharmacologically in 
TEAD4-overexpressing cells with the benzylidene 
lactam compound KNK473 (Fig.  4C). KNK437 
has been shown to inhibit the induction of HSPs, 
including HSP70, HSP40, and HSP105, in vitro.(40) 
Additionally, KNK437 was shown to revert E2 factor 
(E2F) transcription factor 1-mediated HSP40 induc-
tion, which plays a role in promoting colorectal cancer 
tumor growth and metastasis in vitro and in vivo.(41) 
Supporting our hypothesis, treatment of TEAD4-
overexpressing Huh7 cells with 100 μM of KNK437 
abolished the effect of TEAD4 overexpression on 
cell proliferation at 48 and 72  hours posttreatment 
(Fig. 4D). No significant reduction on cell prolifera-
tion was observed in control cells following treatment 
with KNK437.
Taken together, our results demonstrate that 
TEAD4 promotes tumor growth in HCC at least 
partially through direct regulation of the HSP70 
family members. We further showed that the phar-
macologic inhibition of HSP70 induction reverted 
the increased cell proliferation phenotype induced by 
TEAD4 overexpression.
teaD4 Regulates Hsp70 
anD Cell pRoliFeRation 
inDepenDent oF Hippo 
signaling
The transcriptional activity of TEAD proteins is 
highly dependent on the binding of their C-terminal 
protein interaction domain to several coactivators.(42,43) 
Among those cofactors, YAP and TAZ,(44,45) two major 
Hippo signaling pathway transcriptional coactivators, 
are the most well studied. When the Hippo signaling 
pathway is active, YAP and TAZ proteins are located 
in the nucleus, thus binding to TEADs and inducing 
transcription of TEAD downstream targets (Fig. 5A). 
Conversely, when the Hippo pathway is inactive, phos-
phorylation of YAP and TAZ allows TEADs to bind to 
other cofactors and activate alternative transcriptional 
targets (Fig.  5A).(46) The role of TEAD4 in HCC 
Fig. 3. TEAD4 regulates cell differentiation and proliferation and the expression of HSP70 family genes. (A) Heatmap showing the top 
50 differentially expressed genes in TEAD4-overexpressing Huh7 cells. (B) Volcano plot of –log10 adjusted P value against log2 fold change 
to illustrate the differentially expressed genes between TEAD4-overexpressing Huh7 cells and control cells. Red dots indicate differentially 
expressed genes (adjusted P < 0.05). (C-E) GSEA plots show selected significantly enriched gene sets in TEAD4-overexpressing cells: 
Hallmark gene sets from (C) MSigDB database, (D) HSP family gene set, and (E) GO gene sets from the MSigDB database. (F) The 
Huh7 cell line was transiently transfected with a vector overexpressing TEAD4 and the corresponding control. RNA was extracted 
at different time points. mRNA expression levels of HSPA1A (left) and HSPA6 (right) were measured by qRT-PCR using GAPDH 
as the internal control. Data are shown as fold change relative to control. Results represent three independent experiments. Statistical 
significance was determined by the Mann-Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001. Data are mean ± SD. Abbreviations: E2F, E2 
factor; FDR, false discovery rate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LATS1, large tumor suppressor kinase 1; mRNA, 
messenger RNA; mTORC1, mammalian target of rapamycin complex 1; NFKB, nuclear factor kappa B; ox, overexpression; TJP2, tight 
junction protein 2; TNFa, tumor necrosis factor alpha; UV, ultraviolet.
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carcinogenesis has so far been linked to the Hippo sig-
naling pathway.(19,21) Interestingly, analysis of RNA-seq 
data from TEAD4-overexpressing Huh7 cells revealed 
no significant change in well-known targets and/or 
effectors of the Hippo signaling pathway (e.g., YAP1, 
large tumor suppressor kinase 1 [LATS1], tight junction 
protein 2 [TJP2], and CTGF; Fig. 3B) or in the Hippo 
signaling pathway as a whole (q > 0.01 GO; Fig. 3E), 
Fig. 4. TEAD4 impacts cell proliferation by directly binding HSP70 promoters and associated enhancers. (A) TEAD4 ChIP-seq peaks 
at the promoters of HSPA6 and HSPA1A, and regions called as TEAD4 enhancers within 100 kb of HSPA6 and HSPA1A, with TEAD4 
binding motifs labeled. Enhancers and promoters are labeled as red and blue blocks, respectively. The TEAD4 binding motif logos are 
shown below the track, and positions in the HSPA6 and in HSPA1A enhancers harboring this motif are indicated (this motif was also found 
at the promoter of all three genes). Asterisks indicate peaks validated by ChIP-qPCR. (B) ChIP-qPCR showing enrichment for TEAD4 
binding at the HSPA6 promoter and the HSPA1A enhancer. CTGF was used as a positive control. (C) Representative immunostain of 
TEAD4 and HSP70 on human HCCs. Magnification ×40; scale bar 20 μm. (D) Schematic representation of the mechanisms of action 
of KNK437 on HSP70. (E) Proliferation of TEAD4-overexpressing Huh7 cells treated with 100 μM of KNK437 at various time points, 
relative to proliferation at 4 hours. DMSO was used as control. Results represent three independent experiments. Statistical significance 
was determined by the t test; *P < 0.05, **P < 0.01, ***P < 0.001. Data are mean ± SD. Abbreviations: chr, chromosome; h, hours; mRNA, 
messenger RNA; ox, overexpression; RLU, relative light unit; TF, transcription factor.
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suggesting that the oncogenic properties of TEAD4 in 
HCC are independent of the Hippo pathway.
To test the hypothesis that TEAD4 does not 
require Hippo signaling to promote cell proliferation 
in liver cancer cells, we overexpressed TEAD4 in sta-
ble YAP/TAZ-knockdown and control liver cancer cell 
lines (Supporting Fig.  S3A,B; Fig.  5B,C). We first 
confirmed that the stable YAP/TAZ-knockdown cells 
had impaired Hippo signaling, as indicated by reduced 
Cyr61, CTGF, and vimentin expression (Supporting 
Fig.  S3A,B). When TEAD4 was overexpressed 
(Supporting Fig.  S3C), we observed that the prolif-
eration rate was significantly increased in both sta-
ble YAP/TAZ-knockdown and control Huh7 and 
SNU449 cells (P  <  0.001 and P  <  0.05, respectively; 
Fig.  5D), suggesting that the presence or absence of 
the cofactors YAP and TAZ did not alter how TEAD4 
modulates cell proliferation in vitro.
Finally, to confirm that TEAD4 regulates HSP70 
expression independent of Hippo signaling, we mea-
sured HSPA1A and HSPA6 expression in the stable 
YAP/TAZ-knockdown and control cells. In line with 
Fig. 5. The effect of TEAD4 on cell proliferation is independent of expression of cofactors YAP and TAZ. (A) Schematic representation 
of TEAD4 transcriptional activity associated with YAP/TAZ cofactor expression. (B) Expression levels of YAP and TAZ were measured 
in stable YAP/TAZ-knockdown (shY/T) and control (shCTR) Huh7 and SNU449 cell lines by qRT-PCR normalized to GAPDH as 
internal control. (C) TEAD4 expression in stably TEAD4-overexpressing and control Huh7 and SNU449 cell lines with knockdown 
of YAP/TAZ or control (shCTR). (D) Proliferation kinetics of stable TEAD4-overexpressing and control Huh7 cell lines with YAP/TAZ 
knockdown or control (shCTR) (left) and in TEAD4-overexpressing and control SNU449 stable cell lines with YAP/TAZ knockdown 
and control (shCTR) (right). (E) HSPA6 and HSPA1A expression levels in TEAD4-overexpressing and control Huh7 cell lines with 
knockdown of YAP/TAZ or control (shCTR) were measured by qRT-PCR using GAPDH as reference. (F) Expression levels of HSPA6 in 
TEAD4-overexpressing and control Huh7 cell lines with knockdown of YAP/TAZ or control (shCTR) were measured by western blot at 
48 and 72 hours posttransfection. Data are shown as fold change to control. Results represent three independent experiments. Statistical 
significance was determined by t test; *P < 0.05, **P < 0.01, ***P < 0.001. Data are mean ± SD. Abbreviations: GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; h, hours; ox, overexpression; sh, short hairpin; VGLL, vestigial-like protein 1.
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our RNA-seq analysis, HSPA1A and HSPA6 were 
up-regulated following TEAD4 overexpression in 
both the stable YAP/TAZ-knockdown and the control 
cells (Fig.  5E; Supporting Fig.  S3D), demonstrating 
that TEAD4 regulates HSP70 expression indepen-
dent of its YAP and TAZ coactivators. Additionally, 
we also performed western blot analysis to evaluate 
if the changes observed at the RNA level were also 
observed at the protein level. Indeed, we observed that 
the overexpression of TEAD4 in cells with knockdown 
of YAP/TAZ led to an increased level of HSP70 at 
the protein level (Fig. 5F).
Our results suggest that the oncogenic effects of 
TEAD4 overexpression in HCC are, at least in part, 
independent of the expression of the Hippo signaling 
YAP and TAZ coactivators.
Discussion
TEAD4 is a member of the TEAD transcriptional 
enhancer factor family composed of four members 
(TEAD1-4). Deregulation of TEAD4 expression, as 
with other members of the family, has been exten-
sively reported in several tumor types.(16,47,48) In the 
present study, we showed that TEAD4 promotes cell 
proliferation and tumor growth in HCC by directly 
regulating HSP70 family members through, at least in 
part, a Hippo-independent mechanism.
After confirming the overexpression of TEAD4 in 
a subset of HCC in the TCGA data set, we evalu-
ated the functional relevance of TEAD4 up-regula-
tion in HCCs by performing a series of in vitro and 
in vivo experiments. We demonstrated that TEAD4 
overexpression promoted tumor growth, cell prolifera-
tion, and migration in liver cancer cells while TEAD4 
silencing had the opposite effect. Our observations are 
consistent with the oncogenic role played by TEAD4 
in other tumor types. Indeed, it has been shown that 
down-regulation of TEAD4 expression hampers can-
cer cell proliferation and invasiveness in in vitro and 
in vivo models of colorectal and gastric cancers.(48,49) 
Our findings demonstrate that TEAD4 also acts as 
an oncogene in HCC.
As a transcription factor, TEAD4 regulates the 
transcription of many genes, activating or repressing 
several downstream pathways, such as cell growth, 
differentiation, and apoptosis.(11) Consistent with 
the role of TEAD4 in cell differentiation, the gene 
expression profile of TEAD4-overexpressing Huh7 
cells showed up-regulation of pathways, such as sper-
matogenesis, EMT, and myogenesis. Surprisingly, 
chaperone folding and HSP pathways were also found 
to be significantly enriched in TEAD4-overexpressing 
cells. Specifically, we identified two members of the 
HSP70 family (HSPA6 and HSPA1A) as among the 
most up-regulated genes. HSP70B and HSP70-1, the 
protein products of HSPA6 and HSPA1A, respectively, 
are members of the ubiquitous and highly conserved 
HSP70 family of molecular chaperones. In normal 
cell conditions, chaperones are expressed at very low 
levels, ensuring the correct folding and transport of 
newly synthesized proteins.(50) However, chaperone 
levels increase during cell cycle and development(51) 
as well as in response to cellular stress as occurs, for 
example, in tumors. Overexpression of HSP70 family 
members has been shown to play an oncogenic role in 
different cancer types,(35,36) including HCC.(37,38) In 
HCC, HSP70 has been reported to drive cell migra-
tion,(52) and genetic ablation of HSP70 was able to 
markedly impair chemically induced liver tumori-
genesis and tumor progression.(38) Notably, HSP70 
is a clinically important marker in HCC diagnosis; 
HSP70 expression, together with that of glutamine 
synthetase and glypican 3, is commonly used to dif-
ferentiate early and low-grade tumors from dysplastic 
nodules.(53)
Our reanalysis of the ChIP-seq data from the 
HepG2 cell line(25) revealed two mechanisms by which 
TEAD4 can regulate the expression of HSP70 fam-
ily genes; first by binding sites mapped less than 1 kb 
from the TSS of HSPA6 and second through TEAD4 
enhancer regions ~50  kb upstream of the HSPA6 
promoter and ~47 kb downstream of HSPA1A. Both 
putative TEAD4 enhancers and the HSP70 promoter 
regions were found to harbor TEAD4 binding motif, 
and we confirmed the direct binding of TEAD4 at 
these loci by ChIP-qPCR in TEAD4-overexpressing 
Huh7 cells. In fact, we demonstrated that the increased 
cell proliferation resulting from TEAD4 overexpres-
sion was reversed by the pharmacologic inhibition of 
HSP70. We note that although KNK437 is a nonspe-
cific HSP70 inhibitor, it has been shown to inhibit 
only inducible HSPs but has no effect on the expres-
sion of constitutively expressed HSP family mem-
bers, including HSC70 and HSP90.(40) Therefore, 
although KNK437 is not specific to HSP70, it 
would only inhibit HSPs induced following TEAD4 
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overexpression. Our results thus indicate that the 
oncogenic effect of TEAD4 in HCC acts through its 
regulation of HSP70.
The transcription factor TEAD4 and its coact-
ivators YAP and TAZ are considered major down-
stream effectors of the conserved Hippo signaling 
pathway.(18) However, in colorectal and prostate can-
cers,(6,15) TEAD4 has been found to play a role in 
EMT and cell proliferation independent of YAP/
TAZ expression. Here, we demonstrated that TEAD4 
overexpression increased liver cancer cell prolifer-
ation independent of the expression of YAP/TAZ. 
Supporting our YAP/TAZ-knockdown experiments, 
our RNA-seq data from TEAD4-overexpressing cells 
revealed no significant changes on Hippo signal-
ing following TEAD4 overexpression. Furthermore, 
we showed that TEAD4 overexpression induced 
HSPA1A and HSPA6 expression in the context of 
YAP/TAZ knockdown. Together, our results indi-
cate that TEAD4 regulates HSP70 expression and 
liver cancer cell proliferation independent of Hippo 
signaling.
In conclusion, we showed that TEAD4 plays an 
oncogenic role in HCC and that its oncogenic effect 
is mediated in part by its regulation of HSP70 genes. 
More importantly, our results unveil a novel role of 
TEAD4 outside its canonical Hippo-dependent 
mechanism.
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